SCHEMBL2358892

SCHEMBL2358892

CCCOC(=O)N(c1cccc(-c2nn(CC)cc2-c2ccncc2)c1C)S(=O)(=O)c1cc(F)ccc1F

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.35
CDC7 O00311 1/20 0.33
DBF4 Q9UBU7 1/20 0.33
MAPK1 P28482 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PPARG P37231 12/20 0.32
PPARD Q03181 12/20 0.32
PPARA Q07869 12/20 0.32
GCGR P47871 1/20 0.32
BRAF P15056 1/20 0.32
MAPK3 P27361 1/20 0.32
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2358799 0.94 MAPK14 (0.39) MAPK14CDC7DBF4MAPK1NPSR1
SCHEMBL2359937 0.94 MAPK14 (0.34) MAPK14CDC7DBF4MAPK1NPSR1
SCHEMBL28039521 0.92 MAPK14 (0.33) MAPK14CDC7DBF4MAPK1BRAF
SCHEMBL2359292 0.91 MAPK14 (0.35) MAPK14CDC7DBF4MAPK1NPSR1
SCHEMBL2359052 0.89 PPARG (0.36) MAPK14PPARGPPARDPPARA
SCHEMBL2359428 0.89 MAPK14 (0.38) MAPK14CDC7DBF4MAPK1NPSR1
SCHEMBL2313322 0.89 MAPK14 (0.35) MAPK14CDC7DBF4MAPK1NPSR1
SCHEMBL14108523 0.89 MAPK14 (0.35) MAPK14CDC7DBF4MAPK1NPSR1
SCHEMBL2360030 0.89 MAPK14 (0.33) MAPK14CDC7DBF4MAPK1GCGR
SCHEMBL2358917 0.88 MAPT (0.34) MAPK14CDC7DBF4MAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011092088-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO claimed
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP disclosed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US disclosed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US disclosed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US disclosed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US disclosed
WO-2011092088-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO disclosed
WO-2011092088-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K15, MAP3K19, CDK3 MAPK14 36/4885CDC7 159/4885DBF4 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.